Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C4025231
Disease: Chronic calcifying pancreatitis
Chronic calcifying pancreatitis 		0.010 AlteredExpression disease BEFREE It was concluded that PSP-S gene expression is specifically reduced in CCP patients. 2525567 1989
CUI: C3714509
Disease: Nutrition Disorders
Nutrition Disorders 		0.010 Biomarker group BEFREE Composition of calculi--at least 95% calcium salts and a degraded form of lithostathine S (formerly called PSP S2-5)--was similar in the Occidental alcoholic and in the tropical form: calcified calculi are probably related to alcohol and nutritional disorders. 1736346 1992
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.010 AlteredExpression disease BEFREE It is concluded that in PSP individuals impaired attention probably results from prenatal developmental abnormalities (possibly on the cellular level) and is likely to be a marker of a biological vulnerability to schizophrenia. 10532621 1999
CUI: C0041671
Disease: Attention Deficit Disorder
Attention Deficit Disorder 		0.010 Biomarker disease BEFREE Analyses of attention and global behaviors, measured at intervals from about 12 to 26 years of age, indicate (a) attentional deficits can be reliably detected in high-risk children who will develop future schizophrenia-spectrum disorders (the prespectrum [PSP] group); (b) these deficits are stable, enduring over time, and appear to reflect a compromised attentional capacity; (c) attention is not affected by the onset of illness in the PSP group; (d) for all subjects, attention and global behaviors follow independent developmental pathways; and (e) behavioral difficulties, but not attention deficits, appear to be highly sensitive to environmental factors, especially rearing by a mentally ill parent. 10532621 1999
CUI: C1263846
Disease: Attention deficit hyperactivity disorder
Attention deficit hyperactivity disorder 		0.010 Biomarker disease BEFREE Analyses of attention and global behaviors, measured at intervals from about 12 to 26 years of age, indicate (a) attentional deficits can be reliably detected in high-risk children who will develop future schizophrenia-spectrum disorders (the prespectrum [PSP] group); (b) these deficits are stable, enduring over time, and appear to reflect a compromised attentional capacity; (c) attention is not affected by the onset of illness in the PSP group; (d) for all subjects, attention and global behaviors follow independent developmental pathways; and (e) behavioral difficulties, but not attention deficits, appear to be highly sensitive to environmental factors, especially rearing by a mentally ill parent. 10532621 1999
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease 		0.050 Biomarker disease BEFREE These data provide evidence for extremely rare apoptotic neuronal death in AD and PSP compatible with the progression of neuronal degeneration in these chronic diseases. 11205141 2000
CUI: C0038868
Disease: Progressive supranuclear palsy
Progressive supranuclear palsy 		0.100 Biomarker disease BEFREE Some of the sporadic disorders (progressive supranuclear palsy [PSP] and corticobasal degeneration) have been referred to by molecular pathologists as primary tauopathies, implicating abnormalities of tau in their pathogenesis. 14502653 2003
CUI: C0949664
Disease: Tauopathies
Tauopathies 		0.050 Biomarker group BEFREE Some of the sporadic disorders (progressive supranuclear palsy [PSP] and corticobasal degeneration) have been referred to by molecular pathologists as primary tauopathies, implicating abnormalities of tau in their pathogenesis. 14502653 2003
CUI: C0393570
Disease: Corticobasal degeneration
Corticobasal degeneration 		0.030 Biomarker disease BEFREE Some of the sporadic disorders (progressive supranuclear palsy [PSP] and corticobasal degeneration) have been referred to by molecular pathologists as primary tauopathies, implicating abnormalities of tau in their pathogenesis. 14502653 2003
CUI: C0233565
Disease: Bradykinesia
Bradykinesia 		0.020 Biomarker phenotype BEFREE We have identified a sporadic parkinsonian syndrome characterised by bradykinesia, a variable response to levodopa, and a mean duration of disease of 9 years, which resembles bodig (Parkinson's-dementia of Guam), and histologically has close similarities with both PSP and postencephalitic parkinsonism. 14502653 2003
CUI: C0011265
Disease: Presenile dementia
Presenile dementia 		0.010 Biomarker disease BEFREE We have identified a sporadic parkinsonian syndrome characterised by bradykinesia, a variable response to levodopa, and a mean duration of disease of 9 years, which resembles bodig (Parkinson's-dementia of Guam), and histologically has close similarities with both PSP and postencephalitic parkinsonism. 14502653 2003
CUI: C0030568
Disease: Parkinson Disease, Postencephalitic
Parkinson Disease, Postencephalitic 		0.010 Biomarker disease BEFREE We have identified a sporadic parkinsonian syndrome characterised by bradykinesia, a variable response to levodopa, and a mean duration of disease of 9 years, which resembles bodig (Parkinson's-dementia of Guam), and histologically has close similarities with both PSP and postencephalitic parkinsonism. 14502653 2003
CUI: C0497327
Disease: Dementia
Dementia 		0.010 Biomarker disease BEFREE We have identified a sporadic parkinsonian syndrome characterised by bradykinesia, a variable response to levodopa, and a mean duration of disease of 9 years, which resembles bodig (Parkinson's-dementia of Guam), and histologically has close similarities with both PSP and postencephalitic parkinsonism. 14502653 2003
CUI: C0038868
Disease: Progressive supranuclear palsy
Progressive supranuclear palsy 		0.100 GeneticVariation disease BEFREE To review the clinical and molecular features of non-Alzheimer's disease (non-AD) dementias, focusing on disorders associated with tau pathology (that is, frontotemporal lobar degeneration [FTLD], corticobasal ganglionic degeneration [CBD], and progressive supranuclear palsy [PSP]) or on disorders with synuclein pathology (that is, dementia with Lewy bodies [DLB] and multisystem atrophy [MSA]). 15101498 2004
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease 		0.050 GeneticVariation disease BEFREE However, although there are currently only limited data available, AgD seems to be clinically distinct from PSP and CBD and shares rather features of (mild) AD or other forms of 'limbic' dementias, among them senile dementia with tangles and the localized form of AD. 15641585 2004
CUI: C0949664
Disease: Tauopathies
Tauopathies 		0.050 Biomarker group BEFREE Further immunohistochemical and biochemical studies revealed that AgD is a four-repeat (4R) tauopathy similar to PSP and corticobasal degeneration (CBD), but distinct from Alzheimer's disease (AD) and Pick's disease. 15641585 2004
CUI: C0236642
Disease: Pick Disease of the Brain
Pick Disease of the Brain 		0.030 Biomarker disease BEFREE Further immunohistochemical and biochemical studies revealed that AgD is a four-repeat (4R) tauopathy similar to PSP and corticobasal degeneration (CBD), but distinct from Alzheimer's disease (AD) and Pick's disease. 15641585 2004
CUI: C0393570
Disease: Corticobasal degeneration
Corticobasal degeneration 		0.030 Biomarker disease BEFREE Further immunohistochemical and biochemical studies revealed that AgD is a four-repeat (4R) tauopathy similar to PSP and corticobasal degeneration (CBD), but distinct from Alzheimer's disease (AD) and Pick's disease. 15641585 2004
CUI: C0011268
Disease: Senile dementia
Senile dementia 		0.010 GeneticVariation disease BEFREE However, although there are currently only limited data available, AgD seems to be clinically distinct from PSP and CBD and shares rather features of (mild) AD or other forms of 'limbic' dementias, among them senile dementia with tangles and the localized form of AD. 15641585 2004
CUI: C0338460
Disease: Argyrophilic grain disease
Argyrophilic grain disease 		0.010 Biomarker disease BEFREE Further immunohistochemical and biochemical studies revealed that AgD is a four-repeat (4R) tauopathy similar to PSP and corticobasal degeneration (CBD), but distinct from Alzheimer's disease (AD) and Pick's disease. 15641585 2004
CUI: C0752347
Disease: Lewy Body Disease
Lewy Body Disease 		0.010 Biomarker disease BEFREE To review the clinical and molecular features of non-Alzheimer's disease (non-AD) dementias, focusing on disorders associated with tau pathology (that is, frontotemporal lobar degeneration [FTLD], corticobasal ganglionic degeneration [CBD], and progressive supranuclear palsy [PSP]) or on disorders with synuclein pathology (that is, dementia with Lewy bodies [DLB] and multisystem atrophy [MSA]). 15101498 2004
CUI: C3887938
Disease: Deuteranomaly
Deuteranomaly 		0.010 Biomarker disease BEFREE However, although there are currently only limited data available, AgD seems to be clinically distinct from PSP and CBD and shares rather features of (mild) AD or other forms of 'limbic' dementias, among them senile dementia with tangles and the localized form of AD. 15641585 2004
CUI: C0038868
Disease: Progressive supranuclear palsy
Progressive supranuclear palsy 		0.100 GeneticVariation disease BEFREE We have recently examined the MAPT locus in progressive supranuclear palsy and found that a haplotype (H1c) on the background of the well-described H1 clade is associated with PSP. 16000317 2005
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.020 Biomarker group BEFREE Due to the similarities between human CaP tumors and the PSP-KIMAP tumors, this preclinical model may supplement the current transgenic models to study CaP more accurately. 15727931 2005
CUI: C0007112
Disease: Adenocarcinoma of prostate
Adenocarcinoma of prostate 		0.010 GeneticVariation disease BEFREE Due to the similarities between human CaP tumors and the PSP-KIMAP tumors, this preclinical model may supplement the current transgenic models to study CaP more accurately. 15727931 2005